PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Sarilumab - Rheumatoid arthritis
PAD Profile : Sarilumab - Rheumatoid arthritis Important
Keywords :
cytokine modulator, IL-6 inhibitor, monoclonal antibody, mab, biologic, RA, Biologic, NICE, immunosuppressant, Interleukin-6 inhibitor, DMARD, bDmard, Disease modulating, Rheumatology,
Brand Names Include :
Kevzara
Important Information :
Severe disease only
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Abatacept
- Certolizumab pegol
- Etanercept
- Golimumab
- Penicillamine
- Rituximab
- Tocilizumab
- Adalimumab
- Sodium aurothiomalate
- Infliximab
- Baricitinib
- Tofacitinib
- Filgotinib
- Upadacitinib
Other Indications
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathway.
02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Rheumatoid Arthritis High Cost DMARDs Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.
18 December 2017
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Sarilumab as a treatment option for the treatment of moderate to severe Rheumatoid Arthritis in line with NICE TA485.
Prescribing will be by hospital specialists only, in line with NICE TA485 using Blueteq initiation and continuation forms. Sarilumab will be considered RED on the traffic light system.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs